Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INSMVery BearishResearch Analysisnews

High materiality10/10

Why Is Insmed Stock Falling Thursday?

Dec 18, 2025, 12:51 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The failure of brensocatib in trials significantly weakens investor confidence in INSM. Historical examples like other biopharmaceutical stocks, such as Acorda Therapeutics after trial failures, show drastic price drops under similar circumstances.

AI summary

What happened, with direct paths to the underlying reporting

INSM stock dropped 15.28% after trial failure announcement. Phase 2b study of brensocatib did not meet efficacy endpoints. Insmed has halted brensocatib's development for CRSsNP immediately. FDA approved Brinsupri, but brensocatib's failure impacts sentiment. Analysts remain positive on Insmed's other programs, despite setbacks.

INSM stock dropped 15.28% after trial failure announcement.
Phase 2b study of brensocatib did not meet efficacy endpoints.
Insmed has halted brensocatib's development for CRSsNP immediately.
FDA approved Brinsupri, but brensocatib's failure impacts sentiment.
Analysts remain positive on Insmed's other programs, despite setbacks.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.